Literature DB >> 12546362

Progressive and extensive dopaminergic degeneration induced by convection-enhanced delivery of 6-hydroxydopamine into the rat striatum: a novel rodent model of Parkinson disease.

Yoshitsugu Oiwa1, Rosario Sanchez-Pernaute, Judith Harvey-White, Krys S Bankiewicz.   

Abstract

OBJECT: A striatal dopamine lesion induces progressive nigral degeneration in rodents; however, intrastriatal injection of 6-hydroxydopamine (6-OHDA) causes only limited lesions due to spontaneous regeneration of the neurons that survive. To make an extensive lesion, the authors used a convection-enhanced delivery (CED) method for intrastriatal infusion of 6-OHDA and evaluated the animals for a model of Parkinson disease (PD).
METHODS: Different doses of 6-OHDA were infused into the unilateral striatum in rats by using the CED method. The dopaminergic neuronal degeneration was evaluated based on morphological, biochemical, and behavioral measurements until 8 weeks postlesion. Due to the wide distribution of the drug, CED of 20 microg of 6-OHDA into the striatum was sufficient to obtain a progressive and extensive nigrostriatal lesion as defined by morphological (> 80% cell loss in the substantia nigra [SN]) and biochemical (> 95% decrease in striatal dopamine) criteria. The extent of the lesion manifested as a stable turning behavior with amphetamine (> 6 turns/minute) and apomorphine (> 4 turns/minute). It also appeared that at I week postlesion the apoptotic markers were maximal in neurons of the SN.
CONCLUSIONS: A rat model of PD with a progressive and extensive dopamine lesion was successfully made by intrastriatal CED of 6-OHDA. In this model, the therapeutic value can be assessed using behavioral, biochemical, and histochemical measurements. The delay of nigral neuronal death with respect to the time of 6-OHDA administration may provide a therapeutic window for testing neuroprotective strategies.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12546362     DOI: 10.3171/jns.2003.98.1.0136

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  10 in total

1.  Reflux-free cannula for convection-enhanced high-speed delivery of therapeutic agents.

Authors:  Michal T Krauze; Ryuta Saito; Charles Noble; Matyas Tamas; John Bringas; John W Park; Mitchel S Berger; Krystof Bankiewicz
Journal:  J Neurosurg       Date:  2005-11       Impact factor: 5.115

2.  Long-term safety of combined intracerebral delivery of free gadolinium and targeted chemotherapeutic agent PRX321.

Authors:  Dale Ding; Charles W Kanaly; Thomas J Cummings; James E Herndon; Raghu Raghavan; John H Sampson
Journal:  Neurol Res       Date:  2009-12-21       Impact factor: 2.448

3.  Protective effect of metabotropic glutamate mGluR5 receptor elimination in a 6-hydroxydopamine model of Parkinson's disease.

Authors:  Yolanda D Black; Danqing Xiao; Daniela Pellegrino; Anil Kachroo; Anna-Liisa Brownell; Michael A Schwarzschild
Journal:  Neurosci Lett       Date:  2010-09-18       Impact factor: 3.046

4.  Testing the contributions of striatal dopamine loss to the genesis of parkinsonian signs.

Authors:  Vanessa Franco; Robert S Turner
Journal:  Neurobiol Dis       Date:  2012-03-29       Impact factor: 5.996

5.  Molecular profiling of a 6-hydroxydopamine model of Parkinson's disease.

Authors:  Sang J Na; Anthony G DiLella; Edward V Lis; Keith Jones; David M Levine; David J Stone; J F Hess
Journal:  Neurochem Res       Date:  2010-02-19       Impact factor: 3.996

6.  Convection-enhanced delivery of free gadolinium with the recombinant immunotoxin MR1-1.

Authors:  Dale Ding; Charles W Kanaly; Darrell D Bigner; Thomas J Cummings; James E Herndon; Ira Pastan; Raghu Raghavan; John H Sampson
Journal:  J Neurooncol       Date:  2009-11-07       Impact factor: 4.130

7.  Human interleukin-10 gene transfer is protective in a rat model of Parkinson's disease.

Authors:  Louisa C Johnston; Xiaomin Su; Kathleen Maguire-Zeiss; Karen Horovitz; Irina Ankoudinova; Dmitry Guschin; Piotr Hadaczek; Howard J Federoff; Krystof Bankiewicz; John Forsayeth
Journal:  Mol Ther       Date:  2008-06-10       Impact factor: 11.454

8.  Dissociation of progressive dopaminergic neuronal death and behavioral impairments by Bax deletion in a mouse model of Parkinson's diseases.

Authors:  Tae Woo Kim; Younghye Moon; Kyungjin Kim; Jeong Eun Lee; Hyun Chul Koh; Im Joo Rhyu; Hyun Kim; Woong Sun
Journal:  PLoS One       Date:  2011-10-17       Impact factor: 3.240

9.  Selective COX-2 inhibition prevents progressive dopamine neuron degeneration in a rat model of Parkinson's disease.

Authors:  Rosario Sánchez-Pernaute; Andrew Ferree; Oliver Cooper; Meixiang Yu; Anna-Liisa Brownell; Ole Isacson
Journal:  J Neuroinflammation       Date:  2004-05-17       Impact factor: 8.322

10.  Endogenous repair by the activation of cell survival signalling cascades during the early stages of rat Parkinsonism.

Authors:  Nga-Ping Lui; Liang-Wei Chen; Wing-Ho Yung; Ying-Shing Chan; Ken Kin-Lam Yung
Journal:  PLoS One       Date:  2012-12-12       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.